4.8 Article

The hSSB1 orthologue Obfc2b is essential for skeletogenesis but dispensable for the DNA damage response in vivo

期刊

EMBO JOURNAL
卷 31, 期 20, 页码 4045-4056

出版社

WILEY
DOI: 10.1038/emboj.2012.247

关键词

apoptosis; DNA damage response; hSSB1; Obfc2b; skeletogenesis

资金

  1. NIH grant [R01 AI037526-18, RO1 HD043997]

向作者/读者索取更多资源

Human single-stranded DNA-binding protein 1 (hSSB1), encoded by OBFC2B, was recently characterized as an essential factor for the initiation of DNA damage checkpoints and the maintenance of genomic stability. Here, we report that loss of Obfc2b in mice results in perinatal lethality characterized by growth delay and skeletal abnormalities. These abnormalities are associated with accumulation of gamma H2ax, apoptosis and defective pre-cartilage condensation, which is essential for normal bone formation. However, deficiency of Obfc2b does not affect the initiation of DNA damage checkpoints, Atm activation, or the maintenance of genomic stability in B lymphocytes and primary fibroblasts. Loss of Obfc2b results in increased expression of its homologue Obfc2a (hSSB2). In contrast to Obfc2b deficiency, depletion of Obfc2a in fibroblasts results in impaired proliferation, accumulation of gamma H2ax and increased genomic instability. Thus, the hSSB1 orthologue Obfc2b has a unique function during embryogenesis limited to cell types that contribute to bone formation. While being dispensable in most other cell lineages, its absence leads to a compensatory increase in Obfc2a protein, a homologue required for the maintenance of genomic integrity. The EMBO Journal (2012) 31, 4045-4056. doi:10.1038/emboj.2012.247; Published online 31 August 2012

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques

Koen K. A. Van Rompay, Lark L. Coffey, Tania Kapoor, Anna Gazumyan, Rebekah I. Keesler, Andrea Jurado, Avery Peace, Marianna Agudelo, Jennifer Watanabe, Jodie Usachenko, Anil Singapuri, Ramya Immareddy, Amir Ardeshir, Jackson B. Stuart, Stylianos Bournazos, Jeffrey V. Ravetch, Paul J. Balderes, Ivo C. Lorenz, Shannon R. Esswein, Jennifer R. Keeffe, Pamela J. Bjorkman, Qiao Wang, Charles M. Rice, Margaret R. MacDonald, Michel C. Nussenzweig, Davide F. Robbiani

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Article Multidisciplinary Sciences

Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody

Shannon R. Esswein, Harry B. Gristick, Andrea Jurado, Avery Peace, Jennifer R. Keeffe, Yu E. Lee, Alisa V. Voll, Mohsan Saeed, Michel C. Nussenzweig, Charles M. Rice, Davide F. Robbiani, Margaret R. MacDonald, Pamela J. Bjorkman

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Article Biochemistry & Molecular Biology

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Christopher O. Barnes, Anthony P. West, Kathryn E. Huey-Tubman, Magnus A. G. Hoffmann, Naima G. Sharaf, Pauline R. Hoffman, Nicholas Koranda, Harry B. Gristick, Christian Gaebler, Frauke Muecksch, Julio C. Cetrulo Lorenzi, Shlomo Finkin, Thomas Hagglof, Arlene Hurley, Katrina G. Millard, Yiska Weisblum, Fabian Schmidt, Theodora Hatziioannou, Paul D. Bieniasz, Marina Caskey, Davide F. Robbiani, Michel C. Nussenzweig, Pamela J. Bjorkman

Article Microbiology

A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations

Qiao Wang, Eleftherios Michailidis, Yingpu Yu, Zijun Wang, Arlene M. Hurley, Deena A. Oren, Christian T. Mayer, Anna Gazumyan, Zhenmi Liu, Yunjiao Zhou, Till Schoofs, Kai-hui Yao, Jan P. Nieke, Jianbo Wu, Qingling Jiang, Chenhui Zou, Mohanmmad Kabbani, Corrine Quirk, Thiago Oliveira, Kalsang Chhosphel, Qianqian Zhang, William M. Schneider, Cyprien Jahan, Tianlei Ying, Jill Horowitz, Marina Caskey, Mila Jankovic, Davide F. Robbiani, Yumei Wen, Ype P. de Jong, Charles M. Rice, Michel C. Nussenzweig

CELL HOST & MICROBE (2020)

Editorial Material Immunology

Neutralizing hepatitis B

Davide F. Robbiani

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

Article Immunology

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Alexandra Schafer, Frauke Muecksch, Julio C. C. Lorenzi, Sarah R. Leist, Melissa Cipolla, Stylianos Bournazos, Fabian Schmidt, Rachel M. Maison, Anna Gazumyan, David R. Martinez, Ralph S. Baric, Davide F. Robbiani, Theodora Hatziioannou, Jeffrey Ravetch, Paul D. Bieniasz, Richard A. Bowen, Michel C. Nussenzweig, Timothy P. Sheahan

Summary: The study shows that combined use of hu-mAbs is effective for prevention and therapy of SARS-CoV-2 infection, but in vivo protection is influenced by intact effector function.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Article Multidisciplinary Sciences

Evolution of antibody immunity to SARS-CoV-2

Christian Gaebler, Zijun Wang, Julio C. C. Lorenzi, Frauke Muecksch, Shlomo Finkin, Minami Tokuyama, Alice Cho, Mila Jankovic, Dennis Schaefer-Babajew, Thiago Y. Oliveira, Melissa Cipolla, Charlotte Viant, Christopher O. Barnes, Yaron Bram, Gaelle Breton, Thomas Hagglof, Pilar Mendoza, Arlene Hurley, Martina Turroja, Kristie Gordon, Katrina G. Millard, Victor Ramos, Fabian Schmidt, Yiska Weisblum, Divya Jha, Michael Tankelevich, Gustavo Martinez-Delgado, Jim Yee, Roshni Patel, Juan Dizon, Cecille Unson-O'Brien, Irina Shimeliovich, Davide F. Robbiani, Zhen Zhao, Anna Gazumyan, Robert E. Schwartz, Theodora Hatziioannou, Pamela J. Bjorkman, Saurabh Mehandru, Paul D. Bieniasz, Marina Caskey, Michel C. Nussenzweig

Summary: After infection with SARS-CoV-2, antibody levels against the spike protein decrease significantly, but the number of memory B cells remain unchanged, indicating an evolving humoral response at 6.2 months after infection.

NATURE (2021)

Article Cell Biology

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Zijun Wang, Julio C. C. Lorenzi, Frauke Muecksch, Shlomo Finkin, Charlotte Viant, Christian Gaebler, Melissa Cipolla, Hans-Heinrich Hoffman, Thiago Y. Oliveira, Deena A. Oren, Victor Ramos, Lilian Nogueira, Eleftherios Michailidis, Davide F. Robbiani, Anna Gazumyan, Charles M. Rice, Theodora Hatziioannou, Paul D. Bieniasz, Marina Caskey, Michel C. Nussenzweig

Summary: The IgA response to SARS-CoV-2 was characterized in a cohort of 149 convalescent individuals after COVID-19 diagnosis. IgA responses in plasma generally correlated with IgG responses, and B cells producing IgM, IgG, and IgA were derived from common progenitor cells. Notably, IgA dimers were found to be 15 times more potent than IgA monomers against SARS-CoV-2, suggesting their potential value for protection and vaccine efficacy.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Article Hematology

miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms

Tomasz Sewastianik, Juerg R. Straubhaar, Jian-Jun Zhao, Mehmet K. Samur, Keith Adler, Helen E. Tanton, Vignesh Shanmugam, Omar Nadeem, Peter S. Dennis, Vinodh Pillai, Jianli Wang, Meng Jiang, Jianhong Lin, Ying Huang, Daniel Brooks, Mary Bouxsein, David M. Dorfman, Geraldine S. Pinkus, Davide F. Robbiani, Irene M. Ghobrial, Bogdan Budnik, Petr Jarolim, Nikhil C. Munshi, Kenneth C. Anderson, Ruben D. Carrasco

Summary: The deletion of miR-15a/16-1 cluster in murine GC B cells induces moderate but widespread molecular and functional changes, leading to the development of mature B-cell neoplasms resembling human extramedullary plasmacytoma and lymphoma. The low expression levels of miR-15a/16 in human primary EP, primarily associated with del(13q) loss, highlights the tumor-suppressor role of this cluster in plasma cell and B-cell malignancies.
Article Immunology

Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease

Marianna Agudelo, Martin Palus, Jennifer R. Keeffe, Filippo Bianchini, Pavel Svoboda, Jiri Salat, Avery Peace, Anna Gazumyan, Melissa Cipolla, Tania Kapoor, Francesca Guidetti, Kai-Hui Yao, Jana Elsterova, Dana Teislerova, Ales Chrdle, Vaclav Honig, Thiago Oliveira, Anthony P. West, Yu E. Lee, Charles M. Rice, Margaret R. MacDonald, Pamela J. Bjorkman, Daniel Ruzek, Davide F. Robbiani, Michel C. Nussenzweig

Summary: The study revealed the human neutralizing antibody response to TBEV, showing that the most potent neutralizing antibodies were found in individuals who recovered from natural infection. These antibodies also neutralized other tick-borne flaviviruses, and structural analysis identified a conserved epitope near the lateral ridge of EDIII. Prophylactic or early therapeutic antibody administration was effective at low doses in mice lethally infected with TBEV.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Article Multidisciplinary Sciences

Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice

Raoul De Gasparo, Mattia Pedotti, Luca Simonelli, Petr Nickl, Frauke Muecksch, Irene Cassaniti, Elena Percivalle, Julio C. C. Lorenzi, Federica Mazzola, Davide Magri, Tereza Michalcikova, Jan Haviernik, Vaclav Honig, Blanka Mrazkova, Natalie Polakova, Andrea Fortova, Jolana Tureckova, Veronika Iatsiuk, Salvatore Di Girolamo, Martin Palus, Dagmar Zudova, Petr Bednar, Ivana Bukova, Filippo Bianchini, Dora Mehn, Radim Nencka, Petra Strakova, Oto Pavlis, Jan Rozman, Sabrina Gioria, Jose Camilla Sammartino, Federica Giardina, Stefano Gaiarsa, Qiang Pan-Hammarstrom, Christopher O. Barnes, Pamela J. Bjorkman, Luigi Calzolai, Antonio Piralla, Fausto Baldanti, Michel C. Nussenzweig, Paul D. Bieniasz, Theodora Hatziioannou, Jan Prochazka, Radislav Sedlacek, Davide F. Robbiani, Daniel Ruzek, Luca Varani

Summary: The bispecific IgG1-like molecule CoV-X2 can simultaneously bind two independent sites on the RBD, prevent spike binding to ACE2, neutralize SARS-CoV-2 and its variants, and protect mice from disease in a mouse model of SARS-CoV-2 infection. This demonstrates the feasibility and efficacy of targeting non-overlapping RBD epitopes with IgG-like bispecific antibodies.

NATURE (2021)

Editorial Material Immunology

A dark side to NS1 antibodies?

Davide F. Robbiani, Daniel Ruzek

Summary: The NS1 protein of flaviviruses has become a focus of research for its potential in vaccine and immunotherapeutic development. However, a recent study has revealed a potential dark side to NS1, linking it to the development of self-reactive antibodies.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Article Multidisciplinary Sciences

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Allison J. Greaney, Tyler N. Starr, Christopher O. Barnes, Yiska Weisblum, Fabian Schmidt, Marina Caskey, Christian Gaebler, Alice Cho, Marianna Agudelo, Shlomo Finkin, Zijun Wang, Daniel Poston, Frauke Muecksch, Theodora Hatziioannou, Paul D. Bieniasz, Davide F. Robbiani, Michel C. Nussenzweig, Pamela J. Bjorkman, Jesse D. Bloom

Summary: The study found that although the human immune system can produce antibodies that target diverse RBD epitopes, in practice, the polyclonal response to infection tends to be skewed towards a single class of antibodies targeting an epitope that is already undergoing rapid evolution.

NATURE COMMUNICATIONS (2021)

Article Immunology

Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein

Filippo Bianchini, Virginia Crivelli, Morgan E. Abernathy, Concetta Guerra, Martin Palus, Jonathan Muri, Harold Marcotte, Antonio Piralla, Mattia Pedotti, Raoul De Gasparo, Luca Simonelli, Milos Matkovic, Chiara Toscano, Maira Biggiogero, Veronica Calvaruso, Pavel Svoboda, Tomas Cervantes Rincon, Tommaso Fava, Lucie Podesvova, Akanksha A. Shanbhag, Andrea Celoria, Jacopo Sgrignani, Michal Stefanik, Vaclav Honig, Veronika Pranclova, Tereza Michalcikova, Jan Prochazka, Giuditta Guerrini, Dora Mehn, Annalisa Clabbattini, Hassan Abolhassani, David Jarrossay, Mariagrazia Uguccioni, Donata Medaglini, Qiang Pan-Hammarstroem, Luigi Calzolai, Daniel Fernandez, Fausto Baldanti, Alessandra Franzetti-Pellanda, Christian Garzoni, Radislav Sedlacek, Daniel Ruzek, Luca Varani, Andrea Cavalli, Christopher O. Barnes, Davide F. Robbiani

Summary: Using coldspot-guided antibody discovery, neutralizing antibodies to highly conserved viral epitopes were identified. Antibody fp.006 binds the fusion peptide and cross-reacts against coronaviruses. Antibody hr2.016 targets the stem helix and neutralizes SARS-CoV-2 variants. Antibody sd1.040 binds to subdomain 1 and synergizes with antibody rbd.042 for neutralization.

SCIENCE IMMUNOLOGY (2023)

Article Immunology

Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course

Jonathan Muri, Valentina Cecchinato, Andrea Cavalli, Akanksha A. A. Shanbhag, Milos Matkovic, Maira Biggiogero, Pier Andrea Maida, Jacques Moritz, Chiara Toscano, Elaheh Ghovehoud, Raffaello Furlan, Franca Barbic, Antonio Voza, Guendalina De Nadai, Carlo Cervia, Yves Zurbuchen, Patrick Taeschler, Lilly A. Murray, Gabriela Danelon-Sargenti, Simone Moro, Tao Gong, Pietro Piffaretti, Filippo Bianchini, Virginia Crivelli, Lucie Podesvova, Mattia Pedotti, David Jarrossay, Jacopo Sgrignani, Sylvia Thelen, Mario Uhr, Enos Bernasconi, Andri Rauch, Antonio Manzo, Adrian Ciurea, Marco B. L. Rocchi, Luca Varani, Bernhard Moser, Barbara Bottazzi, Marcus Thelen, Brian A. Fallon, Onur Boyman, Alberto Mantovani, Christian Garzoni, Alessandra Franzetti-Pellanda, Mariagrazia Uguccioni, Davide F. Robbiani

Summary: We found that antibodies against specific chemokines are commonly present in COVID-19 convalescents and are associated with favorable disease outcomes and a decreased risk of long COVID development at 1 year post-infection. These chemokine antibodies are also found in HIV-1 infection and autoimmune disorders, but target different chemokines compared to COVID-19. Monoclonal antibodies derived from COVID-19 convalescents that bind to the chemokine N-loop impair cell migration. Naturally occurring chemokine antibodies may modulate the inflammatory response and have therapeutic potential.

NATURE IMMUNOLOGY (2023)

暂无数据